Here are 1-3 brief analogies for Outset Medical (OM):

• Dyson for dialysis machines

• Apple for kidney care technology

• Peloton for home dialysis

• Tablo Hemodialysis System: A compact console for hemodialysis that integrates water purification, on-demand dialysate production, and connectivity for use in acute and home care settings.

Outset Medical (OM) primarily sells its Tablo Hemodialysis System to other companies, specifically healthcare providers.

While Outset Medical does not publicly disclose the specific names of its major customer companies, its customer base consists primarily of the following types of organizations:

• Hospitals and Health Systems: These are large organizations comprising multiple hospitals, clinics, and other healthcare facilities that provide acute care, including inpatient dialysis services. This category includes large integrated delivery networks (IDNs).
• Outpatient Dialysis Clinics and Providers: Specialized healthcare centers dedicated to providing chronic dialysis treatment to patients. These providers facilitate dialysis care in both in-clinic and home settings.

Leslie Trigg, Chair and CEO

Leslie Trigg has served as CEO of Outset Medical since November 2014 and was elected Chair in 2022. Prior to joining Outset Medical, she was an Executive in Residence at Warburg Pincus, a private equity firm, from March 2012 to March 2014. She also held roles at Lutonix, a medical device company, including Executive Vice President, from January 2010 to February 2012, which was later acquired by CR Bard. Additionally, she served as Chief Business Officer of AccessClosure, another medical device company, from September 2006 to June 2009, which was acquired by Cardinal Health.

Renee Gaeta, Chief Financial Officer

Renee Gaeta was appointed Chief Financial Officer of Outset Medical, effective June 3, 2025. She previously served as CFO of Shockwave Medical from February 2024 until its acquisition by Johnson & Johnson in May 2024. Prior to that, she was the CFO of Eko Health, a cardiopulmonary digital health company, from July 2021 to February 2024. Ms. Gaeta has also served on the board of directors of Candel Therapeutics and previously on the board of SeaSpine Holdings Corporation until it merged with Orthofix Medical.

Michael Aragon, Chief Medical Officer

Michael Aragon has served as Chief Medical Officer, guiding the company's clinical strategy since September 2018. He is board certified in Internal Medicine and Nephrology and was previously the founding partner and President of North Texas Kidney Consultants-DFW for 14 years.

Marc Nash, Executive Vice President of R&D, Operations and Service

Marc Nash has overseen Outset Medical's operations and R&D since 2023. His prior roles at Outset Medical include General Manager of Outset Mexico, Vice President of Manufacturing, and Senior Director of Operations.

1. Regulatory Challenges and FDA Scrutiny: Outset Medical faces significant risks related to regulatory compliance and oversight from the Food and Drug Administration (FDA). In 2023, the company received a warning letter from the FDA regarding the marketing of its TabloCart accessory beyond its original clearance, leading to a pause in product shipments and a substantial decline in stock value. Additionally, in May 2024, a Class I recall was initiated for certain Tablo Hemodialysis Systems due to the potential leaching of toxic compounds from silicone tubing, posing serious health consequences for patients. Although some regulatory hurdles are reportedly behind the company, the potential for future issues with new product features or compliance remains a significant concern.

2. Financial Performance and Path to Profitability: The company faces considerable financial risks, primarily its inability to achieve consistent profitability and its high cash burn rate. Outset Medical experienced a 14.1% year-over-year revenue decline in 2024, and a 13% decrease in the prior year, raising concerns about its ability to achieve sustainable growth. The company is currently consuming substantial amounts of cash to support its sales expansion, manufacturing, and research and development, a financial profile described as "highly speculative" compared to its more profitable competitors. The path to profitability is contingent on accelerating growth, improving gross margins, and effective management execution. There are also ongoing concerns about the potential need for additional financing.

3. Intense Competition and Market Adoption: Outset Medical operates in a highly competitive global dialysis equipment market dominated by well-established players such as Fresenius Medical Care, Baxter International, and DaVita. While its Tablo Hemodialysis System offers an innovative, portable, and simplified solution with advantages in operational efficiency, ease of use, and cost reduction, its technological lead is not guaranteed as competitors are actively investing in home hemodialysis solutions. The company's success is heavily dependent on the broad market acceptance of Tablo by both healthcare providers and patients, and financial pressures on customers, such as capital budget constraints and staffing shortages, could negatively impact sales. Furthermore, the anticipated expansion of the home hemodialysis market may not materialize as expected, affecting Outset Medical's growth prospects.

Outset Medical (OM) operates in several addressable markets for its Tablo Hemodialysis System:

• The global hemodialysis machines market was valued at approximately USD 13.53 billion in 2023 and is projected to grow to USD 17.78 billion by 2030.
• The global dialysis equipment market was valued at USD 11.66 billion in 2025 and is anticipated to reach USD 18.63 billion by 2035.
• For the home-based use of its Tablo system, Outset Medical has projected a total addressable market of USD 8.9 billion in the U.S.
• The acute care market in the U.S. for Tablo also represents a multi-billion dollar opportunity.

Outset Medical (OM) is anticipated to drive future revenue growth over the next two to three years through several key strategies and developments:

1. Expansion of Tablo Console Installed Base: The company continues to prioritize and achieve growth in its Tablo Hemodialysis System installed base across both acute and home care settings. This expansion directly leads to increased revenue. For instance, the Tablo installed base reached nearly 6,000 consoles, growing 10% in 2024. By the end of 2025, over 1,000 acute care sites in the United States were utilizing Tablo, performing approximately 1 million treatments annually and over 3 million cumulative treatments.
2. Growth in Recurring Revenue from Consumables and Services: A significant and growing portion of Outset Medical's total revenue comes from recurring streams, specifically from Tablo consumables and service contracts. In 2023, recurring revenue constituted over 50% of total revenue. This trend continued into 2024, with recurring revenue growing 21% to $83.9 million. For 2025, recurring revenue grew 6% to $88.7 million. The company expects recurring revenue to continue to perform well as the installed base grows, contributing to total revenue growth even if console sales remain flat.
3. Launch of Next-Generation Tablo Platform: A significant future driver is the FDA clearance of its next-generation Tablo platform, which occurred in early 2026, with a commercial launch expected in the second quarter of 2026. This new product introduction is projected to contribute to Outset Medical's revenue growth, with management projecting 5%–9% revenue growth for 2026.
4. Strategic Insourcing Agreements with Large Health Systems: Outset Medical has secured major new customer agreements, including with one of the largest national health systems in the country, encompassing over 100 facilities, for the insourcing of dialysis. This strategy allows healthcare providers to create in-house dialysis programs, enhancing operational and clinical outcomes and representing a substantial growth opportunity for Outset Medical.
5. Deepening Penetration in Acute and Home Dialysis Markets: The company is focused on expanding the Tablo footprint in both acute and home care settings. This includes adding new accounts in the acute and subacute settings, as well as deepening the patient census and volume in existing home programs and attracting new market entrants to home dialysis. This dual-market penetration is a consistent theme in their growth strategy.

Share Issuance

• In April 2021, Outset Medical completed a public offering, selling 2,945,864 shares of its common stock at $53.50 per share, resulting in net proceeds of approximately $149.7 million to the company.
• The company has historically financed its operations and capital expenditures through the sale of common stock and redeemable convertible preferred stock.
• In Q1 2025, the company secured $169 million in equity financing, which, along with debt restructuring, bolstered its financial stability.

Inbound Investments

• Outset Medical has primarily financed its operations and capital expenditures through various means, including sales of redeemable convertible preferred stock and common stock, as well as debt financing.
• The company recapitalized with new capital in 2025 to fund operations through cash flow breakeven and beyond.
• Outset Medical benefited from $169 million in equity financing in Q1 2025, enhancing its financial runway.

Capital Expenditures

• For the nine months ended September 30, 2024, capital expenditures for purchases of property and equipment were $869 thousand, a decrease from $2.387 million in the comparable prior-year period.
• In the last 12 months leading up to March 2026, capital expenditures amounted to approximately $798,000.
• In Q4 2025, Outset Medical invested $223K in capital expenditures, primarily focused on funding long-term assets and infrastructure.